objective To evaluate the diagnostic performance of two commercially available ELISA kits, Novalisa â and Ridascreen â , for the detection of antibodies to Taenia solium, compared to serological diagnosis of neurocysticercosis (NCC) by LLGP-EITB (electro-immunotransfer blot assay using lentillectin purified glycoprotein antigens).
Introduction
Neurocysticercosis (NCC) is a common parasitic infection of the central nervous system, responsible for a sizable number of cases of epilepsy and other neurological morbidity in most of the world [1] [2] [3] . In endemic areas, around one-third of all epilepsy cases are attributable to cerebral cysticercosis infections [3] . Diagnosis of NCC is difficult mainly due to the pleomorphism of clinical manifestations and the heterogeneity of immunological and radiological findings between cases, arising from the variable number, location, evolutionary stage and size of the parasitic lesions, as well as the immune response of the host [1, 4] .
Brain imaging using computed tomography (CT), magnetic resonance imaging (MRI), or both, is the cornerstone of human NCC diagnosis [1] . However, images are in many cases not conclusive on the aetiology of lesions and can miss NCC lesions. In particular, CT may miss small cysts or lesions close to the skull bones or in the posterior fossa, and MRI is poorly sensitive to calcified cysts [5, 6] .
Sound use of serological assays may complement imaging results. Immunodiagnosis of cysticercosis can be carried out by detecting antibodies to the parasite or parasitic antigens. Antibody detection is often more sensitive but the presence of specific antibodies may result from exposure to the parasite or resolved infections and thus does not necessarily reflect current infection [7] . In cases of light infection burden (e.g. single cyst patients) or in cases where lesions are already degenerated or resolved, antibody levels may not be detectable [7] [8] [9] . Antigen detection is less sensitive and will test positive only in cases with multiple living parasites -a piece of information that may be of importance to define treatment strategies. Cases of degenerating or resolved NCC will most frequently be antigen negative [7, 10, 11] .
The assay of choice for antibody detection is an electro-immunotransfer blot (western blot) assay using lentillectin purified glycoprotein antigens (LLGP-EITB) [7, 12] . This assay is reported to have a sensitivity of 98% in patients with more than a single lesion and does not detect cross-reactive antibodies induced by other infections. The LLGP-EITB, however, is technically complicated, requires sophisticated laboratory capacity and is not widely available. Despite previously published data pointing to inferior diagnostic performance [13, 14] , many investigators still use antibody detection by ELISA for diagnostic purposes [15] [16] [17] [18] [19] . Commercial ELISA assays are offered by most diagnostic laboratories in the United States and Europe, and globally ELISA for antibody is the most commonly performed serologic assay for cysticercosis. We evaluated the diagnostic performance of two commercially available ELISA kits for the detection of antibodies to Taenia solium.
Materials and methods

Study population
Anonymised archive serum samples from patients with viable parenchymal brain cysticercosis (n = 45, positive on LLGP-EITB for cysticercosis to two or more antibody bands), samples from patients with resolved, calcified NCC (n = 45, positive on LLGP-EITB for cysticercosis to one [n = 13] or two [n = 32] antibody bands) and with other cestode parasites (hymenolepiasis, n = 45 and cystic hydatid disease, n = 45, all negative on LLGP-EITB) were simultaneously evaluated using two commercially available antibody-detecting ELISA kits.
Enzyme-linked immunosorbent assay (ELISA) tests
Two commercial assays (Novalisa â Taenia solium IgG [NovaTec Immundiagnostica GmbH, Dietzenbach, Germany, Kit 1] and Ridascreen â Taenia solium IgG, [R-Biopharm AG, Darmstadt, Germany, Kit 2]) were selected on the basis of a previous study by a different group [13] . Two kits of each assay were acquired from the manufacturers, and samples were processed following the instructions in the package insert of each kit. In brief, the test in Kit 1 required 1 ll of serum (1:100-diluted test samples, 10 ll of serum in 1 ml of buffer) that was incubated in microtiter strip wells pre-coated with T. solium antigens, followed by washing and addition of enzyme conjugate (Protein A), and then, immune complexes are visualised by adding tetramethylbenzidine (TMB) as a substrate. The reaction is stopped with sulphuric acid, and absorbance is read at 450/620 nm. It includes a substrate blank, negative control, cut-off control and a positive control. All of them should meet pre-defined absorbance value ranges; otherwise, the test is not valid and must be repeated. Results are calculated as the sample absorbance value *10 divided by the mean absorbance value of the cut-off control determinations and expressed in Nova Tec Units. The test in Kit 2 required 2 ll of serum (1:50-diluted test samples, 10 ll of serum in 490 ll of buffer), and the process is similar to the one described above for Kit 1.
Results are calculated as a sample index, obtained by dividing the extinction for the sample by the cut-off (the result of average optical density of the negative controls plus a correction factor of 0.150).
Both kits defined a grey zone that cannot be considered clearly positive, and thus, the test outcomes were classified as 'positive', 'negative', or 'intermediate'.
Statistical analysis
Descriptive statistics were calculated by sample group. Positive rates for each kit and their corresponding 95% confidence intervals (CI) were calculated in samples of cases with calcified NCC as a surrogate for sensitivity as compared to LLGP-EITB as the reference gold standard in this subgroup, and negative rates for each kit were calculated in samples with hydatid disease and hymenolepiasis as a surrogate for specificity. In addition, the frequency of cross-reactions in the subgroups with hydatid disease and hymenolepis (positive only, not including intermediate results) was also calculated. Frequencies of cross-reactions were compared between kits using McNemar's chi-squared tests. P-values <0.05 were considered significant. Analyses were carried out using R version 3.1.0 (The R Foundation).
Human subject protection
Samples were collected after written informed consent specifically authorising future use for diagnostic studies. The study and informed consents were reviewed and approved by the main IRB of the Universidad Peruana Cayetano Heredia in Lima, Peru (IRB Code 51070, FWA 00002541).
Results
Samples were from 95 men (52.8%) and 85 women, with a mean age of 34.3 years (SD 18.4). The distribution of men and women was not significantly different between the three groups (chi-squared test, P-value = 0.092). Individuals with hymenolepiasis (mean age 24.7 years) were younger than those with viable or calcified NCC (mean age 36.8 and 37.4 years, respectively) or hydatid disease (mean age 38.4 years); thus, the distribution by age significantly differed between the three groups (KruskalWallis test, P-value <0.001).
Of As the size of the groups was arbitrarily defined, we did not calculate positive or negative predictive values. However, an overall concordance with the EITB as the gold standard was calculated for the samples of patients with viable NCC (n = 45), and both hydatid disease and hymenolepiasis together (n = 90). Cohen 0 s kappa statistics were À0.04 and À0.136 (agreement is worse than that expected for chance) for kits 1 and 2, respectively, not much improved by assigning all intermediate results as concordant (kappa statistics 0.010 and À0.022, respectively).
Comparison of the performance of both kits showed a difference in sensitivity with viable NCC (McNemar's chi-squared test exact P-value = 0.004) but not with calcified NCC (P-value >0.05). Furthermore, these kits were significantly different in terms of likelihood of detecting cross-reactions using sera from patients with cystic hydatid disease (P-value <0.001), and there was a trend for different frequency of cross-reactions with sera from patients with hymenolepiasis (McNemar's chi-squared test exact P-value = 0.1336).
Discussion
Our data show poor sensitivity of both commercially available cysticercosis antibody detection ELISA kits to specific antibodies in patients with NCC, despite the high expected sensitivity and specificity values reported by the producing companies. Sensitivity was even lower for resolved, calcified NCC. This subgroup is likely to have low titres of antibody [20] but even so all these samples had tested positive on LLGP-EITB, with 32 (71%) of them reacting with more than one diagnostic protein band.
The rates of cross-reactions for sera with cystic hydatid disease were very high, 84% and 56%, respectively. The potential for cross-reactions between cysticercosis and hydatidosis had been discussed in the literature and previously demonstrated for older assays [21] [22] [23] . Cross-reactions with hymenolepiasis were less frequent but still occurred in one sample for one kit and in five samples in the other. Hymenolepis nana is a very frequent parasite in poor regions of the world where NCC is endemic [24] . Hymenolepiasis is more frequent in children, which should have contributed to a younger mean age in this group.
A prior study [13] compared five commercial ELISA assays using a set of 14 confirmed NCC sera, 100 known antibody-positive sera without neuroimaging results and 60 samples from heterologous parasitoses, including small subgroups of several parasitic infections. The overall performance of all the kits evaluated was unsatisfactory. Departing from their findings, we attempted a more exhaustive evaluation by expanding the sample groups into a better characterisation of the cysticercosis patients (including separate groups for calcified and viable NCC) and testing a large number of sera from patients with the two more common potentially cross-reactive cestode infections, hymenolepiasis and hydatid disease. Despite the fact that the two kits we used were the ones with better results in that study, their performance in this expanded assessment was quite poor.
Our study has limitations. While we selected two ELISA assays easily available in the market, we may have missed other less known kits with better performance. There are reports in the literature of recently identified antigens that perform well in exploratory testing and have improved specificity including recombinant and synthetic molecules [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] but to the best of our knowledge, ELISAs using these antigens are not yet commercially available (Akira Ito and Sukwan Handali, personal communication, 2017) . Theoretically, a highly specific antigen could be used in higher concentrations and thus potentially also improve assay sensitivity and overall assay performance.
In summary, our results demonstrate a marked performance inferiority of both tested kits for the diagnosis of NCC via antibody detection compared to the LLGP-EITB assay as a standard. Modifications of the current version of the LLGP-EITB test have been proposed, the most promising of which replaces the native antigen mix (dependent on availability of Taenia solium cysts) by synthetic or recombinant antigens [33] . If the performance of the assay is not affected, this new version would make it more reproducible and widely accessible. Antibody ELISA detection would require additional testing independent of its results, and as such, it should not be used for the diagnosis of neurocysticercosis.
